BeiGeneの空売り状況は、投資家がBeiGeneの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

BeiGene (NASDAQ:BGNE) 株価情報, 空売り情報

BeiGene

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

BeiGene, Ltd. - American Depositary Shares

BeiGene Ltd

The Q3 earnings report for Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) was released on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Couchbase beat estimated earnings by 38.0%, reporting an EPS of $-0.05 versus an estimate of $-0.08.
Revenue was up $5.82 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.03 in the previous quarter, leading to a 15.0% drop share price change the next day.
Here's a look at Couchbase's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.15</td>
<td>-0.14</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.10</td>
<td>-0.06</td>
<td>-0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>51.08M</td>
<td>48.56M</td>
<td>46.56M</td>
<td>43.10M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>51.59M</td>
<td>51.33M</td>
<td>50.09M</td>
<td>45.81M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Couchbase <a href="https://www.benzinga.com/quote/BASE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BASE

Insights into Couchbase Q3 Earnings

Quarterly Dividend Increase The company's Board of Directors has approved an increase in its quarterly dividend from $0.37 per share to $0.39 per share, an increase of 5%, or $1.56 on an annualized basis. The quarterly dividend is payable on January 27, 2025, to shareholders of record at the close of business January 2, 2025.
 &nbsp;

Dividends

The Campbell's Company Increases Quarterly Dividend From $0.37 To $0.39 Per Share

Offerings

LUNR

Intuitive Machines Launches $65M Public Offering Of Class A Common Stock Alongside $10M Private Placement With Boryung Corporation

Biotech

General

XAIR

Beyond Cancer Secures Approval From Israeli Ministry Of Health For Phase 1b Trial Combining Low Volume Ultra-High Concentration Nitric Oxide With Anti-PD-1 Therapy In Solid Tumor Patients

NOTV

Inotiv Q4 2024 Adj. EPS $(0.73) Down From $(0.38) YoY, Sales $130.417M Down From $140.740M YoY

Fourth Quarter and FY25 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Q4FY25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp; &nbsp; $867M&nbsp; &nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue YoY Growth Rate</td>
<td colspan="1" rowspan="1">9.7&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Income&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp; $135M&nbsp; &nbsp;&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Margin</td>
<td colspan="1" rowspan="1">15.6&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">FY25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$3.15B&nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue YoY Growth Rate</td>
<td colspan="1" rowspan="1">11.5&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Income</td>
<td colspan="1" rowspan="1">$540M&nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Margin</td>
<td colspan="1" rowspan="1">17&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
These statements are forward-looking and actual results may differ materially. Refer to the Forward Looking Statements section below for information on the factors that could cause our actual results to differ materially from these statements. Pure has not reconciled its guidance for non-GAAP operating income and non-GAAP operating margin to their most directly comparable GAAP measures because certain items that impact these measures are not within Pure's control and/or cannot be reasonably predicted. Accordingly,&nbsp;reconciliations of these non-GAAP financial measures guidance to the corresponding GAAP measures are not available without unreasonable effort.

Guidance

PSTG

Pure Storage Sees Q4 Revenue $867M Vs $856.93M Est.; FY25 Revenue $3.15B Vs $3.13B Est.

Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.03 by 133.33 percent. The company reported quarterly sales of $263.80 million which missed the analyst consensus estimate of $285.82 million by 7.70 percent. This is a 4.21 percent decrease over sales of $275.41 million the same period last year.

Earnings Misses

CURV

Torrid Holdings Q3 2024 GAAP EPS $(0.01) Misses $0.03 Estimate, Sales $263.80M Miss $285.82M Estimate

Discount retailers Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), Dollar Tree Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) and Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) will look to win over investors when each company reports third-quarter financial<a href="https://www.benzinga.com/earnings"> results this week</a>.
Here's a look at their earnings estimates and what analysts are saying.
<h2 class="wp-block-heading">Dollar General</h2>
The Goodlettsville, Tennessee-based company is set to report third-quarter financial results before the market opens Thursday, Dec. 5.
According to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">from Benzinga Pro</a>, analysts expect:
<ul>
<li>Third-quarter revenue of $10.15 billion, up from $9.69 billion in last year's third quarter, </li>
<li>Earnings per share of 94 cents, down from $1.26 in last year's third quarter. </li>
</ul>
The company has beaten analyst estimates for revenue in six of the last 10 quarters, as well as estimates for earnings per share in five of the last 10 quarters.
Data from <a href="https://www.placer.ai/blog/dollar-stores-ahead-of-the-holidays">Placer.ai</a> shows third quarter visits to Dollar General were up 4.8% year-over-year — positive in all the months tracked for the quarter. The report said discount and dollar store leaders like Dollar General are showing consistent strength in the retail space.
Oppenheimer analyst Rupesh Parikh currently has a Perform rating and no price target. 
There are low expectations for Dollar General and a risk of lower guidance from the company, he said. It could also see pressure from the impact of several hurricanes in the south and the continued macroeconomic backdrop.
"On the top line, we expect another soft quarter driven by ongoing discretionary category headwinds and expectations for continued pressures on the company's low-end consumer," Parikh said.
Dollar General stock typically struggles after the company reports quarterly results. Shares fell each of the past eight report days, Parikh said, adding, "We remain sidelined with our entire dollar store coverage."
Read Also: <a href="https://www.benzinga.com/insights/analyst-ratings/24/12/42262907/breaking-down-dollar-gen-8-analysts-share-their-views">Breaking Down Dollar Gen: 8 Analysts Share Their Views</a>
<h2 class="wp-block-heading">Dollar Tree</h2>
The Chesapeake, Virginia-based company reports third-quarter financial results before the market opens on Wednesday, Dec. 4.
Analysts expect: 
<ul>
<li>Third-quarter revenue of $7.44 billion, up from $7.32 billion in last year's third quarter. </li>
<li>And third-quarter earnings per share of $1.07, up from last year's 97 cents per share in the third quarter. </li>
</ul>
The company has beaten analyst estimates for revenue in six of the last 10 quarters, plus estimates for earnings per share in six of the last 10 quarters.
Data from Placer.ai shows third quarter visits to Dollar Tree up 5.3% year-over-year, with each month in the quarter up year-over-year.
In the second quarter, Dollar Tree initiated a formal review of strategic alternatives for its Family Dollar business, which include a sale or spin-off. Investors will be looking for an update on how the review is going.
<h2 class="wp-block-heading">Five Below</h2>
The Philadelphia-based company reports third-quarter financial results after the market closes on Wednesday, Dec. 4.
Analysts expect:
<ul>
<li>Third-quarter revenue of $795.4 million, up from $736.4 million in last year's third quarter. </li>
<li>Third-quarter earnings per share of 17 cents, down from 26 cents per share in last year's third quarter. </li>
</ul>
The company has beaten analyst revenue estimates in five of the last 10 quarters and estimates for earnings per share in five of the last 10 quarters.
Data from<a href="https://www.placer.ai/blog/five-below-and-ollies-bargain-outlet-a-pre-holiday-snapshot"> Placer.ai </a>shows third quarter visits for Five Below up 13.8% year-over-year, suggesting a potentially strong quarter for the company. The report highlights Five Below opening a record 205 new stores last year, which will add to its potential growth for the 2024 holiday shopping season.
Telsey analyst Joseph Feldman recently downgraded Five Below stock from Outperform to Sector Perform and lowered the price target from $102 to $95.
The analyst cautioned on the stock with a transition for its business model and leadership changes taking time.
"The company dealt with the last round of tariffs by breaking the $5 price point and gradually increasing prices since then, while quality did not always keep pace, thereby eroding value," Feldman said.
What's Next: Placer.ai said weekly visits to both Dollar Tree and Dollar General locations tend to increase after Black Friday and peak around the last full week before Christmas.
This could make early commentary on the current fourth quarter and guidance important when the companies report.
Similarly, Five Below sees its traffic increase leading up to the Christmas holiday with its busiest day often Super Saturday, or the Saturday before Christmas. Last year, Five Below saw traffic up 337.3% on Super Saturday compared to its daily average.
Price Action: 
<ul>
<li>Dollar General stock is up 1.62% Tuesday to $79.04 versus a 52-week trading range of $72.12 to $168.07. Shares are down 43% year-to-date in 2024.</li>
<li>Dollar Tree stock is down 0.45% to $72.48 on Tuesday versus a 52-week trading range of $60.49 to $151.22. Shares are down 49% year-to-date.</li>
<li>Five Below stock is up 4% to $103.20 at last check Tuesday versus a 52-week trading range of $64.87 to $216.18. Shares are down 52% year-to-date.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41561955/dollar-general-aims-to-draw-customers-from-walmart-amazon-with-holiday-sales-events">Dollar General Aims To Draw Customers From Walmart, Amazon With Holiday Sales Events</a></li>
</ul>
Image: Pixabay

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Trading Ideas

DLTR

FIVE

Dollar General, Dollar Tree, Five Below Q3 Earnings Preview: Can Discount Retailers Rebound Ahead Of Holidays?

Couchbase Expects Q4 Total Revenue Of $52.7M - $53.5M, Est. $54.046M

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.42 by 19.05 percent. This is unchanged from the same period last year. The company reported quarterly sales of $831.07 million which beat the analyst consensus estimate of $818.14 million by 1.58 percent. This is a 8.94 percent increase over sales of $762.84 million the same period last year.

Earnings Beats

Pure Storage Q3 Adj $0.50 Beats $0.42 Estimate, Sales $831.07M Beat $818.14M Estimate

Box Sees Q4 FY25 Revenue $279M Vs. $278.544M Est.; Adj. EPS $0.41 Vs. $0.41 Est.

Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) reported quarterly losses of $(4.19) per share which beat the analyst consensus estimate of $(4.43) by 5.42 percent. The company reported quarterly sales of $490.700 million which beat the analyst consensus estimate of $477.248 million by 2.82 percent.

Inotiv FY 2024 Adj. EPS $(4.19) Beats $(4.43) Estimate, Sales $490.700M Beat $477.248M Estimate

Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $51.63 million which beat the analyst consensus estimate of $50.78 million by 1.66 percent. This is a 12.69 percent increase over sales of $45.81 million the same period last year.

Couchbase Q3 2024 Adj EPS $(0.05) Beats $(0.08) Estimate, Sales $51.63M Beat $50.78M Estimate

Fourth Quarter of Fiscal 2025 Financial Outlook
<ul>
<li>Net revenue is expected to be $1.800 billion +/- 5%.</li>
<li>GAAP gross margin is expected to be approximately 50%.</li>
<li>Non-GAAP gross margin is expected to be approximately 60%.</li>
<li>GAAP operating expenses are expected to be approximately $710 million.</li>
<li>Non-GAAP operating expenses are expected to be approximately $480 million.</li>
<li>Basic weighted-average shares outstanding are expected to be 867 million.</li>
<li>Diluted weighted-average shares outstanding are expected to be 877 million.</li>
<li>GAAP diluted net income per share is expected to be $0.16 +/- $0.05 per share.</li>
<li>Non-GAAP diluted net income per share is expected to be $0.59 +/- $0.05 per share.</li>
</ul>
GAAP diluted EPS is calculated using basic weighted-average shares outstanding when there is a GAAP net loss, and calculated using diluted weighted-average shares outstanding when there is a GAAP net income. Non-GAAP diluted EPS is calculated using diluted weighted-average shares outstanding.

MRVL

Marvell Technology Sees Q4 EPS $0.59 +/- $0.05 Vs $0.52 Est.; Revenue $1.80B +/- 5% Vs $1.65B Est.

Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $276.00 million which beat the analyst consensus estimate of $275.17 million by 0.30 percent. This is a 5.53 percent increase over sales of $261.54 million the same period last year.

Box Q3 2025 Adj EPS $0.45 Beats $0.42 Estimate, Sales $276.00M Beat $275.17M Estimate

<h3>Gainers</h3>
<ul>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares rose 318.2% to $7.82 during Tuesday's pre-market session. The market value of their outstanding shares is at $19.6 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) stock rose 15.9% to $0.72. The company's market cap stands at $11.1 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares rose 14.41% to $1.86. The market value of their outstanding shares is at $5.2 million. </li>
<li>Mynd.ai (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYND#AMEX">MYND</a>) stock moved upwards by 13.13% to $2.67. The market value of their outstanding shares is at $121.8 million. </li>
<li>Laureate Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAUR#NASDAQ">LAUR</a>) stock rose 10.09% to $20.73. The market value of their outstanding shares is at $3.1 billion. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares rose 8.91% to $2.81. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares declined by 14.9% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $16.3 million. </li>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares fell 14.31% to $13.84. The market value of their outstanding shares is at $176.0 million. As per the press release, Q3 earnings came out today. </li>
<li>Vision Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) stock decreased by 10.04% to $1.79. The company's market cap stands at $1.6 million. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares fell 9.0% to $0.33. The market value of their outstanding shares is at $21.4 million. </li>
<li>Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock declined by 7.39% to $24.2. The company's market cap stands at $12.2 billion. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock decreased by 7.12% to $0.91. The company's market cap stands at $31.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

ALUR

AMBO

CTNT

ECDA

FRSX

JFBR

LAUR

MYND

PLCE

VMAR

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

South Korean markets staged a sharp recovery Tuesday afternoon after President Yoon Suk Yeol reversed a martial law declaration just hours after its announcement following a unanimous parliamentary <a href="https://www.benzinga.com/24/12/42292488/south-korean-etfs-slide-on-presidents-emergency-martial-law-declaration-protect-the-constitutional-democratic-order">vote against the measure.</a>
The iShares MSCI South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWY#NYSE">EWY</a>), a key vehicle for U.S.-based investors seeking exposure to South Korean equities, pared early losses of over 6% to trade down 1.6% as of 3 p.m. ET.
Similarly, the Franklin FTSE South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLKR#NYSE">FLKR</a>) was down 1%, recovering from steeper declines earlier in the session.
The South Korean won weakened by 0.9%, recovering somewhat from a 2% plunge against the U.S. dollar earlier in the day. 
<h3 class="wp-block-heading">Volatile Tuesday For South Korean Assets</h3>
The day began with a political crisis that rattled global observers and sent South Korean markets into freefall. 
Late Tuesday night in Seoul, Yoon declared martial law during a televised address, claiming it was necessary to counter what he described as &#8220;anti-state forces&#8221; within the opposition.
Yoon accused opposition lawmakers of orchestrating gridlock in parliament, undermining key institutions and weaponizing fiscal policy by proposing a 4 trillion won ($2.8 billion) budget cut to cripple his administration.
Financial markets reacted abruptly, with U.S.-listed Korea-linked ETFs facing their steepest early losses since March 2020 during morning trading. 
The South Korean won tumbled nearly 3%, on track for its worst single-day decline since Nov. 9, 2016, when Donald Trump&#8216;s victory in the U.S. presidential election triggered a global selloff in emerging markets.
<h3 class="wp-block-heading">Chart: South Korean ETFs Rebound Sharply After Parliament Overturns Martial Law</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="744" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03154205/image-24-1024x744.png" alt="" class="wp-image-675330" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03154205/image-24-1024x744.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03154205/image-24-300x218.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03154205/image-24-768x558.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03154205/image-24.png 1486w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The president's sudden declaration triggered chaos. Members of Yoon&#8217;s own party urged him to lift the decree, with lawmakers condemning it as "unconstitutional."
Soldiers stormed the National Assembly building, smashing windows to gain entry and blocking lawmakers from entering.
The crisis drew international attention. U.S. Ambassador to South Korea Philip Goldberg commented on X, stating: "The U.S. Embassy and Department of State are closely tracking President Yoon&#8217;s recent declaration of martial law. The situation is fluid."
In response to the crisis, the Bank of Korea announced plans to hold an emergency meeting Wednesday to assess the potential economic and currency fallout.
The Bank of Korea governor, the minister of finance and other financial authorities vowed to provide an unlimited amount of liquidity to stabilize markets.
As reported by Reuters in New York afternoon hours, Yoon's surprise martial law declaration was swiftly and unanimously overturned by 190 National Assembly members, who defied police and military blockades to cast their votes.
According to South Korean law, the president is required to immediately lift martial law if parliament rejects it with a majority vote.
In a brief statement following the vote, Yoon announced that a cabinet meeting would be convened as soon as possible to address the unfolding situation.
Most of the protesters who had gathered outside the National Assembly returned home after the announcement that martial law would be lifted.
The cabinet meeting convened by Yoon officially confirmed the lifting of the martial law.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42291861/trumps-tariff-plan-risks-economic-pain-for-north-america-goldman-sachs-warns">Trump&#8217;s Tariff Plan Risks Economic Pain For North America, Goldman Sachs Warns</a></li>
</ul>
Photo via Shutterstock.

Asia

Emerging Markets

Emerging Market ETFs

Politics

Global

Markets

ETFs

FLKR

South Korea ETFs, Won Pare Losses As Yoon Makes U-Turn On Martial Law Declaration

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) shares moved upwards by 67.4% to $67.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares rose 48.9% to $2.04. The company's market cap stands at $235.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 22.54% to $1.25. The market value of their outstanding shares is at $89.1 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares rose 21.47% to $9.9. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 19.29% to $1.36. The company's market cap stands at $8.1 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock rose 18.76% to $7.09. The company's market cap stands at $231.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 27.7% to $6.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $205.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 24.36% to $2.89. The market value of their outstanding shares is at $27.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 16.51% to $2.8. The company's market cap stands at $5.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 14.73% to $0.81. The market value of their outstanding shares is at $3.4 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) shares fell 13.78% to $2.63. The company's market cap stands at $68.6 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares fell 12.31% to $0.74. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRS

CTOR

GELS

JANX

KDLY

NSPR

PEPG

PPBT

REVB

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>ZJK Industrial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares rose 188.6% to $18.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares moved upwards by 80.81% to $0.4. The company's market cap stands at $11.9 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) shares increased by 31.6% to $0.88. The market value of their outstanding shares is at $21.7 million. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) shares increased by 30.71% to $3.66. The market value of their outstanding shares is at $123.6 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock increased by 18.32% to $2.97. The market value of their outstanding shares is at $435.8 million. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) stock moved upwards by 17.2% to $2.18. The market value of their outstanding shares is at $560.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) shares decreased by 47.2% to $0.37 during Tuesday's pre-market session. The market value of their outstanding shares is at $46.6 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares decreased by 25.44% to $0.51. The company's market cap stands at $2.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) stock fell 23.52% to $0.57. The market value of their outstanding shares is at $12.3 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) stock fell 14.53% to $0.65. The company's market cap stands at $15.9 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock declined by 14.29% to $0.3. The company's market cap stands at $5.3 million. </li>
<li>JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock decreased by 13.41% to $1.55. The company's market cap stands at $8.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

HOVR

JCSE

OMEX

OPTT

SGBX

SHIM

SOAR

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.41 by 4.88 percent. This is a 4.88 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $1.52 billion which beat the analyst consensus estimate of $1.46 billion by 4.12 percent. This is a 6.84 percent increase over sales of $1.42 billion the same period last year.

Marvell Tech Q3 Adj $0.43 Beats $0.41 Estimate, Sales $1.52B Beat $1.46B Estimate

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

BeiGene (BGNE) has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to...

BeiGene settles litigation against generic filer of Brukinsa

China ADRs have increased to the largest share since late 2021 – GS

BeiGene (BGNE) announced that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esopha...

BeiGene announces EC approval of Tevimbra

European Commission approves products by BeiGene, GSK and Novartis

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – Research Rep...

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And U.S.

Morgan Stanley assumed coverage of BeiGene (BGNE) with an Overweight rating and $300 price target The firm sees BeiGene's Brukinsa continuing to ga...

BeiGene assumed with an Overweight at Morgan Stanley

BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth

ABBV

ARGX

ATAT

BABA

BRDCY

FUJHY

HTHT

KWEB

LEGN

LNVGY

MCHI

QFIN

SVNDY

TCOM

TDOC

UPRO

ZLAB

Press Releases

BeiGene Mourns Death of Beloved Board Member Donald Glazer

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene to Present at the Jefferies London Healthcare Conference

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

BeiGene to Present at Upcoming Investor Conferences

European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

Comments

BeiGene

空売り

BeiGene (NASDAQ:BGNE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル